Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 27th July 2015
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Eurostars backs development of canine cancer drug
Dig lysung down
The drug will be an important contribution to the improvement of cancer treatment in dogs.

Antivascular treatment to receive £1.4m of funding
 
The development of a new antivascular drug to fight cancer in dogs is to receive £1.4m in funding from Eurostars.

French-based pharmaceutical company Ecrins Therapeutics has teamed-up with Dr Barbara Kaser-Hotz from Switzerland's Animal Oncology and Imaging Centre (AOIC) and Dr Susan North from the UK's leading private Small Animal Cancer Treatment Centre (VRCC) to test and develop this new and exciting treatment option.

The company has already invested over two million euros in the development of the treatment and Eurostar's contribution will add a further 1.6 million euros (£1.4m) to the pot.  The project began in April 2015 and it is hoped that the drug will come to market in the few years.

Eurostars is an organisation which supports international innovative projects led by research and development-performing small and medium sized enterprises. With its forward-thinking approach, the organisation supports the development of rapidly marketable innovative products, processes and services that help improve the daily lives of people around the world.

Ecrins Therapeutics, AOIC and VRCC came 19th out of 323 Eurostars eligible applications. They are all now looking forward to working together and playing an important contribution to the improvement of cancer treatment in dogs.

Become a member or log in to add this story to your CPD history

Equine Disease Surveillance report released for Q4 2025

News Story 1
 The latest Equine Disease Surveillance report has been released, with details on equine disease from Q4 of 2025.

The report, produced by Equine Infectious Disease Surveillance, includes advice on rule changes for equine influenza vaccination.

Statistics and maps detail recent outbreaks of equine herpes virus, equine influenza, equine strangles and equine grass sickness. A series of laboratory reports provides data on virology, bacteriology, parasitology and toxicosis.

This issue also features a case study of orthoflavivus-associated neurological disease in a horse in the UK. 

Click here for more...
News Shorts
NSA webinar explores sheep tailing and castration

The National Sheep Association (NSA) is to host a free webinar on the castration and tail docking of lambs.

The webinar, 'Understanding the tailing and castration consultation: A guide for sheep farmers', will be hosted online on Monday, 2 March 2026 at 7.30pm.

It comes during a government consultation into the methods used for these procedures. Farmers are encouraged to engage before the consultation period closes on Monday, 9 March 2026.

The webinar offers clear and actionable guidance to support farmers to contribute meaningfully to the consultation and prepare for potential changes.

On the panel will be former SVS president Kate Hovers, farmer and vet Ann Van Eetvelt and SRUC professor in Animal Health and Veterinary Sciences Cathy Dwyer. Each panel member will utilise their own specialism and expertise to evaluate risks and outcomes to sheep farming.

Find out more about the webinar on the NSA website.